Frontline and Subsequent Therapies for Chronic Lymphocytic Leukemia

Investigating Beyond the First-Generation BTK Inhibitors in CLL

In the first article of a 2-part series, Farrukh Awan, MD, discusses the current landscape of treatment for patients with chronic lymphocytic leukemia and what Burton tyrosine kinase inhibitors are having the most impact for these patients.

Acalabrutinib Improves Long-Term PFS in Patients With High-Risk CLL

Danielle M. Brander, MD, discusses updated results from the ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.

Interpreting the Results of the ELEVATE-TN Trial for Treatment-Naive CLL

Nakhle Saba, MD, discusses the significance of the key findings of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for patients with chronic lymphocytic leukemia.

Acalabrutinib With/Without Obinutuzumab Shows Survival Benefit in CLL

Farrukh Awan, MD, discusses the results of the phase 3 ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.

Choosing BTK Inhibitors Versus Venetoclax as First-Line CLL Therapy

Nilanjan Ghosh, MD, PhD, discusses when a Bruton’s tyrosine kinase inhibitor would be preferred over a BCL-2 inhibitor as first-line therapy for patients with chronic lymphocytic leukemia.